Olutasidenib [1887014-12-1]

TargetMol Chemicals

Olutasidenib [1887014-12-1]

4

1887014-12-1

Chemical

Research Use Only

Olutasidenib

99.59%

C18H15ClN4O2

354.79

Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Olutasidenib is a highly effective, brain penetrant, and selective inhibitor of the mutant Isocitrate dehydrogenase 1 (IDH1) (IC50: 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively).

3 years

C[C@H](Nc1ccc(C#N)n(C)c1=O)c1cc2cc(Cl)ccc2[nH]c1=O

-20°C

12352200